Scinai CEO Letter: $8.1M Committed Orders and Runway to Late 2027 After $5.3M Net Raise
SCNI is trading near its 52-week low of $0.66 (5.1% above the low).
Summary
Scinai's CEO letter reports ~$8.1M in committed customer orders, up from $1.9M at year-end 2025, and ~$5.3M in combined net proceeds from recent financings, supporting an estimated runway to late 2027 and potentially Q3 2028.
Key Events · M&A and Partnerships · SCNI
-
Committed Orders Reach ~$8.1M
Committed Customer Orders stood at approximately $8.1M as of October 20, 2026, versus $1.9M at year-end 2025 — an increase of more than 300% — driven by the ~$5.1M U.S. customer CDMO agreement announced October 13.
-
Combined Net Proceeds ~$5.3M
A ~$1.67M SEPA drawdown with Yorkville plus ~$3.6M net from the $4.0M private placement and warrant exercise (closed October 16) total approximately $5.3M in net proceeds, excluding any future exercise of the new warrants.
-
Runway to Late 2027
Management estimates cash supports operations to late 2027, potentially into Q3 2028 if later project phases are activated and collected; the filing states this does not resolve going-concern uncertainty.
-
~$5.85M Later-Phase Work Uncommitted
Additional clinical manufacturing in late 2027 and H1 2028 carries an indicative ~$5.85M service-fee value but requires agreed scope, pricing and written activation; combined committed and potential services exceed $10M.
Analysis · SCNI · Life Sciences
For the first time, Scinai has attached hard numbers to its order book and cash horizon. Committed Customer Orders of ~$8.1M versus $1.9M at year-end 2025 show the CDMO business is scaling, while combined net proceeds of ~$5.3M — the $1.67M SEPA drawdown plus ~$3.6M net from the $4.0M placement and warrant exercise — fund operations to late 2027, with a possible extension into Q3 2028 if the ~$5.85M of uncommitted later-phase work is activated. That runway estimate is the key fact: it pushes the next equity raise further out, which matters for a company this small that has been funding itself through repeated issuance. The caveats are real — the $5.85M is indicative and uncommitted, the $8.1M is a non-GAAP order measure rather than revenue or backlog, and the filing explicitly says the runway estimate does not resolve going-concern uncertainty.
How filings like this one have moved
In the 30 days to Oct 20, 2026, 29.2% of the 1466 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SCNI was trading at $0.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $427.5K. The 52-week trading range was $0.66 to $15.50. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.